SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?


To: Lazarus who wrote (61216)8/15/2018 3:49:36 AM
From: bruwin1 Recommendation

Recommended By
Lazarus

  Respond to of 78774
 
" ... looking iffy !!!

I'd say this company is a Dog.

Simplified way of looking at Balance Sheet :-

Share Capital + Retained Income(R.I.) = Total Assets - Total Liabilities.

Very important number ---> Retained Income, especially when Share Capital hardly changes, because R.I. comes straight off the Bottom Line after dividends.

From KOOL's latest numbers on Balance Sheet ....



..... approximately (217,3 - 187,6)/187,6 = ~16% Increase in fall of "Retained Income", or Increase in "Accumulated deficit" in the period .....

..... very much as a result of ....



.... Bottom Line losses, which, in turn, I'd say is reflected in ....



But that's JMO .....



To: Lazarus who wrote (61216)8/27/2018 3:15:33 PM
From: Graham Osborn  Read Replies (1) | Respond to of 78774
 
Hey Lazarus, which discount broker do you use for most of your small cap stuff? I ask only because some of them have strange rules on transferability etc.



To: Lazarus who wrote (61216)8/28/2018 12:31:45 PM
From: bull_dozer1 Recommendation

Recommended By
Lazarus

  Read Replies (2) | Respond to of 78774
 
Zacks Investment Research, Inc. upgrades CESCA THERAPEUTICS INC from HOLD to BUY.
— 7:15 AM ET 08/21/2018

Thomson Reuters/Verus upgrades CESCA THERAPEUTICS INC from HOLD to BUY.
— 5:21 PM ET 08/20/2018